v3.25.1
Revenue Recognition and Accounts Receivable (Tables)
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
(In millions)
Three Months Ended March 31, 2025 (a)
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$1,019.8 $552.8 $141.8 $402.5 $2,116.9 
Generics871.9 2.7 134.3 117.4 1,126.3 
Total Viatris$1,891.7 $555.5 $276.1 $519.9 $3,243.2 
(In millions)Three Months Ended March 31, 2024
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$1,178.8 $541.8 $184.1 $404.4 $2,309.1 
Generics986.6 2.1 133.7 222.0 1,344.4 
Total Viatris$2,165.4 $543.9 $317.8 $626.4 $3,653.5 
The following table presents net sales on a consolidated basis for select key products for the three months ended March 31, 2025 and 2024, respectively:
Three Months Ended March 31,
(In millions)20252024
Select Key Global Products
Lipitor ®
$388.0 $388.9 
Norvasc ®172.3 176.3 
Lyrica ®112.6 114.2 
Viagra ®98.5 100.7 
EpiPen® Auto-Injectors96.7 80.2 
Creon ®82.4 75.0 
Celebrex ®
63.4 72.2 
Zoloft ®
60.2 58.0 
Effexor ®
59.3 59.4 
Xalabrands37.1 42.5 
Select Key Segment Products
Yupelri ®$58.3 $55.2 
Dymista ®42.8 48.2 
Amitiza ®33.3 33.0 
Xanax ®32.3 34.5 
____________
(a)The Company does not disclose net sales for any products considered competitively sensitive.
(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.
(c)Amounts for the three months ended March 31, 2025 include the impact of foreign currency translations compared to the prior year period.
(d)Refer to intellectual property matters included in Note 17 Litigation for additional information regarding Yupelri® and Amitiza®.
Disaggregation of Revenue, Variable Consideration
The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three months ended March 31, 2025 and 2024, respectively:
Three Months Ended
March 31,
(In millions)
2025 (a)
2024
Gross sales$5,570.2 $6,174.6 
Gross to net adjustments:
Chargebacks(1,158.0)(1,244.2)
Rebates, promotional programs and other sales allowances(970.6)(1,048.3)
Returns(54.3)(60.3)
Governmental rebate programs(144.1)(168.3)
Total gross to net adjustments$(2,327.0)$(2,521.1)
Net sales$3,243.2 $3,653.5 
___________
(a)Amounts for the three months ended March 31, 2025 include the Indore Impact and the impact of foreign currency translations and divested businesses compared to the prior year period.
Schedule of Accounts Receivable, Net Such allowances were comprised of the following at March 31, 2025 and December 31, 2024, respectively:
(In millions)March 31,
2025		December 31,
2024
Accounts receivable, net$1,502.8 $1,547.0 
Other current liabilities1,013.9 989.4 
Total$2,516.7 $2,536.4 
Accounts receivable, net was comprised of the following at March 31, 2025 and December 31, 2024, respectively:
(In millions)March 31,
2025		December 31,
2024
Trade receivables, net$2,584.9 $2,675.3 
Other receivables540.8 546.0 
Accounts receivable, net$3,125.7 $3,221.3